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CD95 (Fas/APO-1)-mediated apoptosis plays an important role in
immunological regulation and is related to the pathogenesis of au-
toimmune diseases. Immunoexpression of CD95 has been reported to
frequently occur in low grade non-Hodgkin lymphomas, especially of
post-germinal center histogenesis, among which those originating in
mucosa-associated lymphoid tissue (MALT lymphomas). However,
there is no report comparing in situ immunoexpression of this marker
in lymphomas and the hyperplastic lymphoid reaction (chronic gastri-
tis) related to Helicobacter pylori infection. The purpose of the present
research was to compare the intensity of lymphoid CD95 immunoex-
pression in 15 cases of H. pylori-related chronic gastritis and 15
gastric MALT lymphomas. CD95 (anti-CD95) was detected by an
immunoperoxidase technique in paraffin sections using the catalyzed
amplification system. Graduation of reaction intensity (percentage of
CD95-positive cells) was semiquantitative, from 1+ to 4+. Nine cases
of chronic gastritis were 4+, five 2+ and one 1+. Three lymphomas
were 4+, three 3+, four 2+, four 1+, and one was negative. Although
14 of 15 lymphomas were positive for CD95, the intensity of the
reaction was significantly weaker compared to that obtained with
gastric tissue for patients with gastritis (P = 0.03). The difference in
CD95 immunoexpression does not seem to be useful as an isolated
criterion in the differential diagnosis between chronic gastritis and
MALT lymphomas since there was overlapping of immunostaining
patterns. However, it suggests the possibility of a pathogenetic role of
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The CD95 (Fas/APO1) antigen belongs
to a family of transmembrane proteins, which
includes the tumor necrosis factor receptor
CD40 and the neural growth factor R, among
others. CD95 is related to the induction of
apoptosis in various cell types. Miyawaki et
al. (1) described CD95 in peripheral B- and
T-lymphoid cells, but not in natural killer
cells, of newborns, infants and adults. The
frequency of Fas-positive lymphocytes in-
creased with age, suggesting that expansion
of this population follows antigenic stimula-
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tion among both B- and T-cells after birth.
These investigators also demonstrated that
additional processes, besides Fas expression,
might be present in order to induce apoptosis
in lymphocytes exposed to antigens.
Lagresle et al. (2) have shown that simple
expression of CD95 in germinal center B-
lymphoid cells did not correlate with in-
creased sensitivity to apoptosis. Additional
activation of these cells was necessary to
induce cell death. These investigators postu-
lated that CD95 might have a late regulatory
function in B-cells in order to prevent prolif-
eration of self-reactive, mutated or low-af-
finity clones. This regulation may involve, at
least in part, down-regulation of genes fa-
voring cell survival, such as bcl-2. Möller et
al. (3) detected low levels of APO1 in a
subset of lymphoid follicle center B-blasts
and high levels in B-sinusoidal cells. APO1
was not detected in the follicle mantle zone
or in plasma cells but was shown to be
expressed in CD10-positive B-cells isolated
from tonsils.
APO1 expression was also described in
epithelial cells, especially in the basal layer.
In contrast, satellite cells of autonomous
nervous ganglia and all central nervous sys-
tem cell types do not present APO1. An
increased expression of APO1 in epithelial
and mesothelial cells in contact with inflam-
matory infiltrate was observed and was at-
tributed to the action of cytokines (4).
Little or no expression of APO1 has been
reported in B-lymphoblastic and lympho-
cytic leukemias, Burkitt’s lymphoma, hairy
cell leukemia, and plasmocytoma. There was
strong expression of APO1 in follicle center
cell and mediastinal large B-cell lymphomas
(3).
Nguyen et al. (5) investigated the immu-
noexpression of CD95 in malignant lympho-
mas and reported that 43% of the B-cell
lymphomas were positive, especially those
with low-grade histology (52%). Among the
latter, the lymphocytic (chronic lymphocytic
leukemia) and the mantle cell lymphomas
were generally negative, while mucosa-as-
sociated lymphoid tissue (MALT) and folli-
cular lymphomas were frequently positive
(92 and 64%, respectively). Later studies
have shown that sensitivity to apoptosis by
the CD95 pathway might be altered, as none
of the lymphomas studied by Plumas et al.
(6), regardless of their level of CD95 expres-
sion, had apoptosis induced by the anti-CD95
monoclonal antibody. These investigators
confirmed the low expression of CD95 in
chronic lymphocytic leukemia and mantle
cell lymphomas, and its high expression in
follicular lymphomas.
In a flow cytometric quantitative study,
Seeberger et al. (7) detected moderate ex-
pression of CD95 in normal memory B-
cells, while MALT lymphoma cells presented
low expression. In that study they also showed
that addition of activated T-lymphocytes to
the cell cultures increased CD95 expression
in both cell types, but MALT lymphoma
cells maintained lower levels of this protein.
Further tests showed that both activated cell
types presented low levels of cell death, but
MALT lymphoma cells with higher levels of
CD95 expression were more resistant to ap-
optosis. This indicates that resistance to
CD95-mediated apoptosis (mutation or in-
activation) may be involved in the genesis of
lymphomas.
The pathogenesis of MALT lymphomas
is intriguing since there is evidence that it
may progress from inflammatory processes
such as Helicobacter pylori-induced gastri-
tis or autoimmune diseases (8). To the best
of our knowledge, there are no studies com-
paring in situ protein expression of CD95
cells in H. pylori-related gastritis and gastric
MALT lymphomas. This information might
be relevant to the understanding of the pro-
gression of inflammation to lymphoma, and
as an aid for differential diagnosis when
histological features are ambiguous. The
purpose of the present study was to compare
the immunoexpression of CD95 in histologi-
cal sections diagnosed either as chronic gas-
1399
Braz J Med Biol Res 37(9) 2004
CD95 in gastritis and MALT lymphomas
tritis (H. pylori positive) or gastric MALT
lymphoma.
Material and Methods
Fifteen cases diagnosed as H. pylori-re-
lated intense chronic gastritis and 15 as gas-
tric MALT lymphoma were selected from
our files. Conventional histological sections
stained with hematoxylin and eosin were
reviewed and new sections from paraffin
blocks were placed on sylanized slides for
immunohistochemical study. After hydra-
tion and endogenous peroxidase blocking
with 3% H2O2, antigen retrieval was per-
formed with a 10 mM citrate buffer solution,
pH 6.0, using a steamer (T-Fall®, Dijon,
France), at 90ºC, for 30 min. Slides were
incubated with an anti-CD95/APO1 anti-
body (Dakopatts, Carpinteria, CA, USA, code
M3553) diluted at 1:10 in 1% BSA-PBS,
overnight (18 h) at 4ºC. Specific antibody
binding was detected using the thyramide-
based catalyzed amplification system
(Dakopatts, code K1500). Slides were then
stained with 3,3-diaminobenzidine, counter-
stained with hematoxylin, dehydrated and
mounted with Entellan (Merck, Darmstadt,
Germany, code 107961).
Immunostaining in lymphoid cells was
graded using a 0 to 4+ score, as follows: 0 =
no reactive cells present; 1+ = up to 10%
positive cells; 2+ = >10 to 40% positive
cells; 3+ = >40 to 70% positive cells; 4+ =
>70 to 100% positive cells.
For comparison of immunostaining be-
tween groups the data were analyzed statisti-
cally by the Mann-Whitney test.
Results and Discussion
All 15 cases diagnosed as H. pylori-re-
lated gastritis presented some degree of
CD95-positive lymphocytes: one was graded
as 1+, five as 2+ and nine as 4+ (Figure 1). In
two cases in which immunostaining was very
strong, superficial plasma cells also presented
membrane reactivity.
Among the 15 cases diagnosed as MALT
non-Hodgkin lymphomas, one did not pres-
ent CD95-positive cells, four cases were
graded as 1+, four as 2+, three as 3+, and
three as 4+ (Figure 2). In most cases of both
Figure 1. Chronic gastritis: most lymphocytes show membrane reaction with anti-CD95/
APO1 (arrowheads). Glandular cells (G) are negative (800X; bar 12.5 µm).
Figure 2. MALT lymphoma: neoplastic lymphocytes and glandular epithelium (G) are
negative for reaction with anti-CD95/APO1 (800X; bar 12.5 µm).
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groups foci of CD95-positive epithelial cells
were also present at variable intensity.
Table 1 summarizes the number of cases
and the respective scores for the chronic
gastritis and MALT lymphoma groups. A
statistically significant difference was de-
tected between groups (P = 0.03) in spite of
overlapping degrees of CD95 immunoex-
pression.
In the present study we demonstrated that
14 of 15 MALT lymphomas (93%) were
positive for CD95. This finding is similar to
the data reported by Nguyen et al. (5), in
whose study 11 of 12 cases (92%) were
positive. In the latter study, however, neither
the criteria used to consider a case as posi-
tive nor the pattern of reactivity were re-
ported. Among our lymphomas, only 6 (40%)
presented reactivity of more than 40% of
lymphoid cells (scores 3+ and 4+), in con-
trast to the group with chronic gastritis. This
finding supports the possibility that down-
regulation of CD95 expression might be in-
volved in cell survival during the genesis of
MALT lymphomas.
Seeberger et al. (7) studied 7 cases of
MALT lymphoma and determined CD95
expression quantitatively by flow cytometry.
Three of the patients presented low levels
and 4 very low levels of CD95. In spite of the
different methods used, heterogeneous CD95
immunoexpression in MALT lymphomas
was a finding in common with our results.
On the other hand, these investigators sug-
gested that there might be different degrees
of sensitivity to CD95-mediated apoptosis
among patients and that such sensitivity might
not be related to the level of CD95 expres-
sion. They showed that cases of MALT lym-
phomas with the lowest levels of CD95 ex-
pression were the most sensitive to in vitro
apoptosis (7).
As MALT lymphomas do express CD95,
the mechanism of oncogenesis among them
could be acquisition of resistance to CD95-
mediated apoptosis either by mutation or
inactivation of CD95 (7). It has been re-
cently shown that 5.6% of primary gastric
MALT lymphomas and 14.3% primary gas-
tric large B-cell lymphomas present Fas
(CD95) mutations which might contribute to
the pathogenesis of gastric lymphomas by
inducing involved lymphocytes to resistance
to apoptosis (9). The increased resistance to
apoptosis may also be due to the elevated
expression of bcl-2, especially in lympho-
mas of low histological grade (5). In addi-
tion, other mechanisms of control of apopto-
sis other than the CD95 pathway might be
involved in the genesis of lymphomas.
To the best of our knowledge, no other
study has addressed the in situ immunoex-
pression of CD95 in H. pylori-related chronic
gastritis. Nine of our cases (60%) had strong
and diffuse positivity (score 4+), and in no
instance were lymphocytes totally negative.
Higher levels of CD95 expression in reac-
tive lymphocytes in comparison to MALT
lymphomas were also detected in a quantita-
tive study using flow cytometry (7).
As we did not perform double staining, it
cannot be ascertained which lymphoid sub-
set presented CD95. However, it is highly
probable that both B- and T-lymphocytes
expressed this protein since it has been shown
that stimulation of B-lymphocytes by acti-
vated T-cells elevated their levels of CD95
(7). Our results also support the previous
Table 1. Cases diagnosed as chronic gastritis and
mucosa-associated lymphoid tissue (MALT) lym-
phomas with the respective scores for reaction
with anti-CD95/APO1.
Score Number of cases
Chronic gastritis MALT lymphomas
0 0 1 (6.6%)
1+ 1 (6.6%) 4 (26.6%)
2+ 5 (33.3%) 4 (26.6%)
3+ 0 3 (20%)
4+ 9 (60%) 3 (20%)
See Methods for scoring. The difference between
the two groups (N = 15 each) was statistically
significant (P = 0.03, Mann-Whitney test).
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observation of elevation of CD95 in lym-
phoid infiltrates and adjacent epithelial cells
(4). It has been suggested that damage to
epithelial cells in autoimmune or H. pylori-
related gastritis might occur through CD95-
mediated apoptosis (10,11).
Overlapping of immunostaining patterns
among our cases of chronic gastritis and
lymphomas indicates that the use of CD95
for differential diagnosis is not reliable, in
spite of significantly lower expression in
lymphomas. However, the difference in
CD95 positivity between both groups sup-
ports the hypothesis that down-regulation of
this apoptosis-related protein might play a
role in cell survival during MALT lympho-
magenesis.
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